CLEVELAND, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced the presentation of data from its ongoing phase I clinical trial of MultiStem(r) for individuals following acute myocardial infarction (AMI). Marc Penn, M.D., Ph.D., Director of the Bakken Heart-Brain Institute at the Cleveland Clinic and co-principal investigator of the study, presented summary data yesterday at the annual Transvascular Cardiovascular Therapeutics conference (TCT) in Washington, D.C. where he described the AMI program and the successful administration of MultiStem in the first patient enrolled at the Cleveland Clinic. Dr. Penn reported that MultiStem was delivered safely and tolerated well by the patient following administration.
